RT Journal Article
T1 HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities.
A1 Avramovic, Gordana
A1 Reilly, Maeve
A1 Cullen, Walter
A1 Macías, Juan
A1 McCombe, Geoff
A1 McHugh, Tina
A1 Oprea, Cristiana
A1 Story, Alistair
A1 Surey, Julian
A1 Sabin, Caroline
A1 Bivegete, Sandra
A1 Vickerman, Peter
A1 Walker, Josephine
A1 Ward, Zoe
A1 Lambert, John S
K1 Cascade of care
K1 HCV elimination
K1 Hepatitis C
K1 Integrated HCV care
K1 People who inject drugs (PWID)
K1 System of care
K1 Vulnerable populations
AB Hepatitis C Virus (HCV) is a significant cause of chronic liver disease. Among at-risk populations, access to diagnosis and treatment is challenging. We describe an integrated model of care, Hepcare Europe, developed to address this challenge. Using a case-study approach, we describe the cascade of care outcomes at all sites. Cost analyses estimated the cost per person screened and linked to care. A total of 2608 participants were recruited across 218 clinical sites. HCV antibody test results were obtained for 2568(98•5%); 1074(41•8%) were antibody-positive, 687(60•5%) tested positive for HCV-RNA, 650(60•5%) were linked to care, and 319(43•5%) started treatment. 196(61•4%) of treatment initiates achieved a Sustained Viral Response (SVR) at dataset closure, 108(33•9%) were still on treatment, eight (2•7%) defaulted from treatment, and seven (2•6%) had virologic failure or died. The cost per person screened varied from €194 to €635, while the cost per person linked to care varied from €364 to €2035. Hepcare enhanced access to HCV treatment and cure, and costs were affordable in all settings, offering a framework for scale-up and reproducibility.
YR 2020
FD 2020-09-28
LK http://hdl.handle.net/10668/16343
UL http://hdl.handle.net/10668/16343
LA en
DS RISalud
RD Apr 6, 2025